Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer

US9376425B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Michael D. Bartberger · West Hollywood, US
• Hilary Plake Beck · Emerald Hills, US
• Xiaoqi Chen · Palo Alto, US
• Richard V. Connors · Mesa, US
• Jeffrey Deignan · San Francisco, US
• Jason A. Duquette · Millbrae, US
• John Eksterowicz · Burlingame, US
• Brian M. Fox · Brisbane, US
• Jiasheng Fu · Foster City, US
• Ana Z. Gonzalez Buenrostro · San Mateo, US
• Felix Gonzalez Lopez De Turiso · San Mateo, US
• Darin J. Gustin · Rue de l'Église, US
• Julie Anne Heath · Chico, US
• Michael G. Johnson · San Diego, US
• Frank Kayser · San Francisco, US
• David John Kopecky · West Hollywood, US
• Yihong Li · Millbrae, US
• Zhihong Li · San Jose, US
• Zhihua Ma · Lexington, US
• Joel McIntosh · Pacifica, US
• Julio C. Medina · Redwood City, US
• Jeffrey T. Mihalic · San Francisco, US
• Steven H. Olson · Millbrae, US
• Yosup Rew · Foster City, US
• Philip M. Roveto · San Francisco, US
• Michael J. Schmitt · San Francisco, US
• Daqing Sun · Foster City, US
• Xiaodong Wang · Zhejiang, CN
• Malgorzata Wanska · Camarillo, US
• Christine Weathers · Katy, US

Key dates

• Filing date: Sep 26, 2012
• Grant date: Jun 28, 2016
• Expiry date: Sep 26, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof,wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.